Teva Pharmaceutical Industries Ltd. (TEVA)$34.07
Currency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Teva Pharmaceutical Industries Ltd. (TEVA).
DCF ready
Valuation
31.4x
EV/FCF, 3.2% FCF yield
Quality
17.8%
ROIC, 6.7% FCF margin
Growth
0.7%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 1.0x current ratio
Superinvestors
2
Top: Harry Burn (3.9%)
Strengths to research
- Free cash flow compounded at 12.5% over five years.
- ROIC is strong at 17.8%.
- Debt/equity looks manageable at 0.0x.
- 10 annual periods are available for trend analysis.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for TEVA.
Grade D
42
/ 100
Financial Charts
No financial data available for TEVA (annual).
2 superinvestors own TEVA
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Harry Burn Sound Shore | 3,885,683 | $117M | 3.92% | 0.0% |
| David Einhorn Greenlight Capital | 2,910,729 | $88M | 2.75% | 0.0% |